Illume Fertility Sponsors and Attends Men Having Babies Berlin, Dedicated to Providing Educational and Financial Support for European Fathers-to-Be Seeking Parenting Options
Founder, Medical Director and Partner at Illume Fertility Dr. Mark Leondires Moderated Panel on Finding and Selecting Your Egg Donor; Panelist on the Medical Aspects of Surrogacy
NORWALK, Conn., May 8, 2025 /PRNewswire/ -- Illume Fertility, a leading fertility practice in the tri-state area providing an exceptional patient experience and cutting-edge treatments from award-winning physicians to help patients achieve their fertility and family-building goals, this past weekend, attended Men Having Babies (MHB) Berlin, an international conference dedicated to providing gay men with educational and financial support to achieve parenthood through surrogacy.
Having treated patients from more than 50 countries with 1,500+ successful surrogacy journeys and 15,000+ babies born, Illume Fertility was on hand to provide leadership and guidance to the hundreds of attendees seeking parenting options. Founder, Medical Director and Partner at Illume Fertility Dr. Mark Leondires, moderated a panel entitled Finding and Selecting Your Egg Donor, as well as provided education at the Medical Aspects of Surrogacy, the conference's medical panel.
He shared, "We are incredibly proud to support the Men Having Babies conference in Berlin, which continues to open doors for intended fathers across Europe who are pursuing the dream of parenthood. By connecting these fathers-to-be with vital resources, expert guidance, and a strong network of support, this event empowers these intended parents to take meaningful steps toward building their families. At Illume, we are honored to stand alongside Men Having Babies and are dedicated to making prospective parents' paths to parenthood more accessible, successful, and filled with hope."
Across most of Europe, gay men who wish to become fathers, face serious legal, cultural, and financial obstacles. With over 15,000 future and current gay parents worldwide, MHB is dedicated to helping gay men become parents. While the event is organized by gay parenting organizations, for the first time, special programming was added to the conference specifically designed for prospective heterosexual parents. Illume has sponsored MHB's Berlin conference as well as others domestically for a number of years. Proceeds from sponsorship fees benefit the Gay Parenting Assistance Program (GPAP).
"Since surrogacy in the U.K. still involves significant restrictions, many intended parents choose to travel to the United States for the process instead," said UK dads Doug and Sanjay who chose to work with Illume Fertility after extensive online research and speaking with other LGBTQ+ parents who pursued surrogacy. "Illume's location in Connecticut was perfect for us, as I'm a flight attendant and we visit the East Coast regularly," said Doug. "As soon as we started working with Illume, we also realized how inclusive it was, and that made us feel so welcome."
For more information on LGBTQ+ paths to parenthood, visit illumefertility.com.
About Illume FertilityIllume Fertility is a leading fertility practice in the tri-state area providing a best-in-class patient experience and cutting-edge treatments by award-winning physicians to help patients achieve their fertility and family-building goals. Led by an expert team of nine highly credentialed, board-certified reproductive endocrinologists, many of whom have received Castle Connolly's prestigious Top Doc award, Illume Fertility specializes in a complete range of assisted reproductive technologies (ART) including intrauterine insemination (IUI), in vitro fertilization (IVF), preimplantation genetic testing (PGT) and egg, sperm, and embryo cryopreservation. Recognized as a Healthcare Equality Leader by the Human Rights Campaign for seven consecutive years, Illume Fertility's commitment to inclusive care includes a world-renowned egg donation and gestational surrogacy program, a dedicated team of third-party reproduction experts, and Gay Parents To Be®, an award-winning resource hub offering tailored support for LGBTQ+ family building. Illume Fertility is the only regional fertility clinic with offices in Connecticut and New York offering comprehensive holistic support services, including in-house nutrition counseling, onsite genetic counselors, fertility acupuncture, yoga for fertility, community events, as well as a network of mental health providers focused on fertility and family-building. Illume Fertility is proud of its exceptional success rates and continues to be a leader in patient-centered care, providing compassionate, expert guidance to each prospective parent we serve.
Media ContactStacy Callahan, Astonish Media Group, 917-972-1101, stacy@astonishmediagroup.com, astonishmediagroup.comVictoria Andretta, Illume Fertility, 845-494-7229, vandretta@illumefertility.com, illumefertility.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/illume-fertility-sponsors-and-attends-men-having-babies-berlin-dedicated-to-providing-educational-and-financial-support-for-european-fathers-to-be-seeking-parenting-options-302450609.html
SOURCE Illume Fertility
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
M-novator Demo Day Ignites Medical Innovation, Shaping the Future of MedTech
TAIPEI, June 6, 2025 /PRNewswire/ -- On the opening day of Medical Taiwan 2025, Mosaic Venture Lab, as a partner of the M-novator, is dedicated to acting as a bridge connecting Taiwan's and international innovative energy. Through its investment and ecosystem collaboration platform, it accelerates the growth of global high-quality startups in Taiwan, fosters cross-border collaborations, and brings more international funding and business opportunities to Taiwan's smart healthcare industry. The M-novator startup teams hail from Taiwan, the United States, South Korea, Belgium, and Israel. Examples include US-based InFocus Therapeutics, which focuses on developing RNA-targeted drugs, and Taiwan's own Pulxion, which has made breakthroughs in AI carotid artery detection, showcasing the international vitality of medical innovation. These pioneering startups, whose technologies represent cutting-edge advancements in the medical field, showcased in their Demo Day pitches precision artificial intelligence for diagnostics and data analysis, intuitive digital health platforms, seamless integration of medical devices (such as advanced endoscopes and smart wearables), and data-driven clinical decision support tools. A key theme of Medical Taiwan 2025 is the significant contribution of ecosystem builders in nurturing early-stage startups to achieve global impact. Johnny Yu, Founder and Chairman of CellTech Innovation Venture Studio and Managing Director of Mosaic Venture Lab, delivered a keynote speech on global MedTech trends and pressures, covering population aging, complex regulatory frameworks, and lengthy development cycles. Johnny highlighted key obstacles faced by early-stage startups: the lab-to-market translation gap, complex regulatory hurdles, funding constraints, and the complexities of market entry. He emphasized that ecosystem builders such as accelerators, venture studios, academic incubators, and government innovation departments play a crucial role in overcoming these challenges. Ryan Jin, Manager at Singapore's Centre for Healthcare Innovation, emphasized in his speech that while innovation is crucial, its effective integration into existing healthcare systems requires strategic partnerships. He acknowledged the common difficulties in collaboration between startups and healthcare institutions, citing systemic misalignments, "last-mile" barriers, and a lack of bridging infrastructure. To overcome these issues, Ryan stressed the need for streamlined processes, strong support for innovation adoption, and the establishment of clear communication channels. A highlight of the Demo Day, the panel discussion "Navigating Taiwan's MedTech Ecosystem" featured panelists including Jowy Tani, CEO of Taipei Medical University BioMed Accelerator; Nina Feng, Managing Director of Vivo Capital Taiwan; and Yenchen Huang, Vice President of Diamond Biofund. The panel aims to provide actionable insights for international MedTech and AI startups seeking to enter and thrive in the Taiwanese and Asian markets, focusing on strategies for clinical adoption, supply chain collaboration, and market entry. Mosaic Venture Lab is a venture capital accelerator focused on digital health, smart mobility, and semiconductor innovation. It collaborates with global automotive OEMs and Tier-1 suppliers to drive technological innovation and optimize business models, and is dedicated to discovering and nurturing innovative technologies from Taiwan, Japan, and South Korea to connect with major European and American companies. Media Contact:Jade ChengSr. Project ManagerMosaic Venture Lab - Partner of Medical Taiwan 2025 M-novatorEmail: jc@ Website: View original content to download multimedia: SOURCE Mosaic Venture Lab Co.,Ltd. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 hours ago
- Yahoo
M-novator Demo Day Ignites Medical Innovation, Shaping the Future of MedTech
TAIPEI, June 6, 2025 /PRNewswire/ -- On the opening day of Medical Taiwan 2025, Mosaic Venture Lab, as a partner of the M-novator, is dedicated to acting as a bridge connecting Taiwan's and international innovative energy. Through its investment and ecosystem collaboration platform, it accelerates the growth of global high-quality startups in Taiwan, fosters cross-border collaborations, and brings more international funding and business opportunities to Taiwan's smart healthcare industry. The M-novator startup teams hail from Taiwan, the United States, South Korea, Belgium, and Israel. Examples include US-based InFocus Therapeutics, which focuses on developing RNA-targeted drugs, and Taiwan's own Pulxion, which has made breakthroughs in AI carotid artery detection, showcasing the international vitality of medical innovation. These pioneering startups, whose technologies represent cutting-edge advancements in the medical field, showcased in their Demo Day pitches precision artificial intelligence for diagnostics and data analysis, intuitive digital health platforms, seamless integration of medical devices (such as advanced endoscopes and smart wearables), and data-driven clinical decision support tools. A key theme of Medical Taiwan 2025 is the significant contribution of ecosystem builders in nurturing early-stage startups to achieve global impact. Johnny Yu, Founder and Chairman of CellTech Innovation Venture Studio and Managing Director of Mosaic Venture Lab, delivered a keynote speech on global MedTech trends and pressures, covering population aging, complex regulatory frameworks, and lengthy development cycles. Johnny highlighted key obstacles faced by early-stage startups: the lab-to-market translation gap, complex regulatory hurdles, funding constraints, and the complexities of market entry. He emphasized that ecosystem builders such as accelerators, venture studios, academic incubators, and government innovation departments play a crucial role in overcoming these challenges. Ryan Jin, Manager at Singapore's Centre for Healthcare Innovation, emphasized in his speech that while innovation is crucial, its effective integration into existing healthcare systems requires strategic partnerships. He acknowledged the common difficulties in collaboration between startups and healthcare institutions, citing systemic misalignments, "last-mile" barriers, and a lack of bridging infrastructure. To overcome these issues, Ryan stressed the need for streamlined processes, strong support for innovation adoption, and the establishment of clear communication channels. A highlight of the Demo Day, the panel discussion "Navigating Taiwan's MedTech Ecosystem" featured panelists including Jowy Tani, CEO of Taipei Medical University BioMed Accelerator; Nina Feng, Managing Director of Vivo Capital Taiwan; and Yenchen Huang, Vice President of Diamond Biofund. The panel aims to provide actionable insights for international MedTech and AI startups seeking to enter and thrive in the Taiwanese and Asian markets, focusing on strategies for clinical adoption, supply chain collaboration, and market entry. Mosaic Venture Lab is a venture capital accelerator focused on digital health, smart mobility, and semiconductor innovation. It collaborates with global automotive OEMs and Tier-1 suppliers to drive technological innovation and optimize business models, and is dedicated to discovering and nurturing innovative technologies from Taiwan, Japan, and South Korea to connect with major European and American companies. Media Contact:Jade ChengSr. Project ManagerMosaic Venture Lab - Partner of Medical Taiwan 2025 M-novatorEmail: jc@ Website: View original content to download multimedia: SOURCE Mosaic Venture Lab Co.,Ltd. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 hours ago
- Yahoo
Kelun-Biotech Announces Approximately US$250 Million Placement
CHENGDU, China, June 6, 2025 /PRNewswire/ -- On June 5, 2025, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", announced the placement of 5,918,000 H shares under its general mandate, representing approximately 2.54% of the enlarged share capital of the Company post the placement. The shares were placed at HK$331.8 per share, raising net proceeds of approximately US$250 million. Highlights of the placement include: The offering was widely recognized by a broad-based investors including domestic and international institutional investors. The transaction was multiple times oversubscribed with robust participation from high-quality investors including global long only funds, sovereign wealth funds, and healthcare specialist funds; Due to the robust booking demand, the deal size was upsized from the initially targeted US$200 million at launch to US$250 million, making it the largest follow-on offering in the biopharma industry in the Hong Kong market over the past 12 months; The final offer price represents a 7.58% discount to the last closing price and a 0.89% premium to the average closing price over the past five trading days. The Company primarily intends to use the net proceeds of the placing (i) for the research and development, clinical trials, registration filings, manufacturing and commercialization of its products; (ii) to enhance its internal research and development technology capabilities, strengthen external collaboration, and expand its product pipeline portfolio. Dr. Michael Ge, CEO of Kelun-Biotech, commented: "We are pleased to see continued support from our key existing shareholders, alongside the addition of new, high-profile investors. This reflects the strong recognition of Kelun-Biotech's long-term investment value by international capital markets and specialist investors. With the support of this financing, we aim to further strengthen our pipeline strategy and accelerate global clinical development. This will enable us to unlock the potential of cutting-edge therapies and deliver innovative treatments to benefit more cancer patients." About Kelun-Biotech Kelun-Biotech ( is a holding subsidiary of Kelun Pharmaceutical ( which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. The company focuses on major disease areas such as solid tumors, autoimmune, inflammatory, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. The Company is committed to becoming a leading global enterprise in the field of innovative drugs. At present, the Company has more than 30 ongoing key innovative drug projects, of which 3 projects have been approved for marketing, 1 project is in the NDA stage, and more than 10 projects are in the clinical stage. The company has established one of the world's leading proprietary ADC platforms, OptiDC™, and has 1 ADC project approved for marketing, 1 ADC project in NDA stage, and multiple ADC and novel DC projects in clinical or preclinical research stage. For more information, please visit Media: klbio_pr@ View original content to download multimedia: SOURCE Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Sign in to access your portfolio
